Mount Sinai and SOPHiA GENETICS Partner to Advance Precision Cancer Care

The collaboration will leverage AI-powered genomic analysis to enhance cancer research and testing capabilities at Mount Sinai's Comprehensive Cancer Center.

Apr. 16, 2026 at 1:51pm

Got story updates? Submit your updates here. ›

An extreme close-up X-ray photograph revealing the complex internal structures of a human cell, with ghostly glowing lines and shapes against a dark background, conceptually representing the advanced genomic analysis capabilities that will drive the partnership between Mount Sinai and SOPHiA GENETICS.Cutting-edge genomic analysis will empower Mount Sinai's cancer research and personalized treatment efforts through the hospital's collaboration with SOPHiA GENETICS.Mount Sinai Today

SOPHiA GENETICS, a leader in AI-driven precision medicine, announced a collaboration with the Mount Sinai Health System, a top academic medical center in New York City. Mount Sinai will adopt SOPHiA's AI-powered DDM Platform to strengthen its next-generation sequencing capabilities for blood cancers and solid tumors, enabling faster results, greater efficiency, and deeper genomic insights to support precision oncology.

Why it matters

The partnership combines Mount Sinai's clinical expertise with SOPHiA's advanced analytics, empowering the hospital to interpret complex genomic data at scale and optimize laboratory resources. This will help Mount Sinai's teams focus more on direct patient care and accelerate the delivery of data-driven, personalized cancer treatments.

The details

Mount Sinai, a National Cancer Institute-designated Comprehensive Cancer Center, supports care for over 4,000 oncology patients annually. The hospital's Molecular Pathology team will leverage SOPHiA DDM™ to strengthen its next-generation sequencing capabilities, enabling detection and interpretation of a wide range of genomic variants while improving operational efficiency.

  • The collaboration was announced at the American Association for Cancer Research (AACR) Annual Meeting in San Diego on April 16, 2026.

The players

Mount Sinai Health System

One of the leading academic health systems in the United States, supporting care for more than 4,000 oncology patients annually and designated as a National Cancer Institute Comprehensive Cancer Center.

SOPHiA GENETICS

A global leader in AI-driven precision medicine and the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data to generate real-time, actionable insights for healthcare institutions worldwide.

Jane Houldsworth, Ph.D.

Director of Molecular Oncology Pathology at the Mount Sinai Health System.

John Carey

Managing Director, North America, at SOPHiA GENETICS.

Got photos? Submit your photos here. ›

What they’re saying

“The collaboration between Mount Sinai and SOPHiA GENETICS reinforces our commitment to scientific innovation by integrating powerful digital tools into our workflows to support high-quality, data-driven cancer care. Leveraging SOPHiA DDM™ has enabled us to reduce hands-on analysis time and improve our testing turnaround times, enabling our clinicians to provide better patient care.”

— Jane Houldsworth, Ph.D., Director of Molecular Oncology Pathology, Mount Sinai Health System

“Mount Sinai is widely regarded as one of the world's leading centers for cancer research and was recently ranked No. 1 globally among health care institutions in the Nature AI Index, underscoring its leadership in artificial intelligence and data-driven innovation. We are honored to support their teams with an AI-native platform and global network designed to deliver faster results, greater operational efficiency, and deeper genomic understanding to help shape the future of precision oncology.”

— John Carey, Managing Director, North America, SOPHiA GENETICS

What’s next

The collaboration was announced at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, where SOPHiA GENETICS is exhibiting at booth #4248 from April 17-22, 2026.

The takeaway

This partnership highlights how leading healthcare institutions are leveraging advanced AI-powered genomic analysis platforms to enhance cancer research, improve testing capabilities, and ultimately deliver more personalized, data-driven care to patients. The collaboration underscores SOPHiA GENETICS' mission to democratize access to precision medicine worldwide.